844 related articles for article (PubMed ID: 21200377)
1. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Fisar Z; Hroudová J; Raboch J
Neuro Endocrinol Lett; 2010; 31(5):645-56. PubMed ID: 21200377
[TBL] [Abstract][Full Text] [Related]
2. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers.
Hroudova J; Fisar Z
Neuro Endocrinol Lett; 2010; 31(3):336-42. PubMed ID: 20588251
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of monoamine oxidase activity by cannabinoids.
Fisar Z
Naunyn Schmiedebergs Arch Pharmacol; 2010 Jun; 381(6):563-72. PubMed ID: 20401651
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
[TBL] [Abstract][Full Text] [Related]
5. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
6. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
7. Effect of chlorpromazine, imipramine and lithium on MAO-A and MAO-B activity in rat brain mitochondria.
Nag M
Indian J Exp Biol; 2004 Sep; 42(9):941-4. PubMed ID: 15462192
[TBL] [Abstract][Full Text] [Related]
8. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
9. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.
Ulus IH; Maher TJ; Wurtman RJ
Biochem Pharmacol; 2000 Jun; 59(12):1611-21. PubMed ID: 10799660
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.
García-Fuster MJ; García-Sevilla JA
Psychopharmacology (Berl); 2016 Aug; 233(15-16):2955-71. PubMed ID: 27259485
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of monoamine oxidase A and B in the heart and brain of the rat with amitriptyline, pargyline and pirlindol].
Schraven E; Reibert R
Arzneimittelforschung; 1984; 34(10):1258-60. PubMed ID: 6542783
[TBL] [Abstract][Full Text] [Related]
12. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
13. [3H]8-OH-DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline.
Carli M; Afkhami-Dastjerdian S; Reader TA
J Psychiatry Neurosci; 1996 Mar; 21(2):114-22. PubMed ID: 8820177
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
15. The properties of B-form monoamine oxidase in mitochondria from monkey platelet.
Obata T; Aomine M
Res Commun Mol Pathol Pharmacol; 2009-2010; 122-123():13-26. PubMed ID: 25022028
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species.
Egashira T; Takayama F; Yamanaka Y
Jpn J Pharmacol; 1999 Sep; 81(1):115-21. PubMed ID: 10580379
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of the active site of brain monoamine oxidase.
Youdim MB
Monogr Neural Sci; 1980; 7():176-92. PubMed ID: 6785574
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase A inhibition by fluoxetine: an in vitro and in vivo study.
Mukherjee J; Yang ZY
Synapse; 1999 Mar; 31(4):285-9. PubMed ID: 10051109
[TBL] [Abstract][Full Text] [Related]
19. Interaction of psychotropic drugs with monoamine oxidase in rat brain.
Gnerre C; Kosel M; Baumann P; Carrupt PA; Testa B
J Pharm Pharmacol; 2001 Aug; 53(8):1125-30. PubMed ID: 11518022
[TBL] [Abstract][Full Text] [Related]
20. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
